menu toggle

In conversation with TrakCel: Why successful partnerships can help accelerate advanced therapies

By AmerisourceBergen

Earlier this year, AmerisourceBergen and TrakCel participated to one of the most attended and immersive events for the cell and gene therapy sector: Phacilitate's Advanced Therapies Week.

Being the destination for anyone developing, investing or interested in cell and gene therapies, this conference was the perfect place to share our expertise around the keys to accelerate access for cell and gene therapies, and deliver complete visibility throughout the patient journey.

Watch Vice President, Adherence and Analytics, Jeff Buck, as he joined TrakCel’s cofounder and Vice President of Scientific Affairs and Business Development, Dr. Matthew Lakelin, to discuss how successful partnerships can help increase advanced therapies’ connectivity and speed to market.

Cell and Gene therapy alternative reimbursement models

Interview: Increasing advanced therapies connectivity and speed to market through partnership

Cell and Gene therapy alternative reimbursement models

Learn more about AmerisourceBergen and TrakCel’s integrated platform